Newspaper publication of the unaudited financial results for the q and year ended 30th september 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has informed BSE that its unaudited financial results for Q2 and half-year ended 30 September 2025, approved by the Board on 12 November 2025, were published in the Navprabha and Navhind Times newspapers on 14 November 2025, as required under SEBI (LODR) regulations. Standalone Q2 revenue came in at Rs 1,766.91 lakh, almost flat year-on-year (Rs 1,773.36 lakh), while net profit after tax rose to Rs 52.43 lakh from Rs 50.02 lakh. Sequentially, Q2 PAT more than doubled from Q1's Rs 22.33 lakh. For H1 FY26, revenue dipped marginally to Rs 3,438.58 lakh from Rs 3,482.39 lakh, but PAT improved to Rs 74.76 lakh (vs Rs 66.71 lakh), with EPS of Rs 0.77 versus Rs 0.69. Equity capital remained at Rs 966.10 lakh and reserves stood at Rs 2,407.60 lakh. Full results are available on the company website and BSE.
This is a procedural filing confirming newspaper publication of already-approved quarterly numbers; no new information for investors beyond reaffirming the Q2 results. Modest H1 PAT growth of around 12% YoY on broadly flat revenue suggests margin improvement, which is mildly positive for shareholders.